Home›Allergy & Immunology› Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TB
Mtb antigen-induced IP-10 shows pooled sensitivity 0.81 and specificity 0.88 for latent TBNew Blood Test Marker Shows Promise for Detecting Hidden Tuberculosis Infections
Frontiers in MedicinePublished September 28, 2026DOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider IP-10 as a promising adjunct for LTBI detection, but clinical utility is unproven.
This meta-analysis synthesized data from 24 studies involving 2,014 participants to assess the diagnostic performance of Mycobacterium tuberculosis antigen-induced interferon-gamma-inducible protein 10 (IP-10) for detecting latent tuberculosis infection (LTBI) in high-risk groups. The comparator was not reported.
Pooled estimates showed a sensitivity of 0.81 and a specificity of 0.88. The positive likelihood ratio was 6.93, the negative likelihood ratio was 0.21, and the diagnostic odds ratio was 32.56. The area under the curve was 0.91.
The authors state that IP-10 is a promising biomarker for detecting LTBI and may serve as a useful adjunct to interferon-gamma release assays (IGRAs) and the tuberculin skin test (TST). However, they explicitly note that clinical utility requires further validation. No safety data, adverse events, or tolerability information were reported. Funding sources and conflicts of interest were not reported.
Given the absence of comparator details and the need for further validation, these findings should be interpreted as supportive of a potential adjunctive role for IP-10 rather than as evidence for replacing current diagnostic strategies.
How this fits prior evidence
This meta-analysis extends prior coverage of TB diagnostics and management by evaluating a novel biomarker, Mtb antigen-induced IP-10, for LTBI detection. Prior items addressed pulmonary rehabilitation in post-TB lung disease, biopsychosocial determinants of TB outcomes, TB prevalence in malnourished children, fluoroquinolone resistance during treatment, and weight-based ethambutol dosing in children. Unlike those, this review focuses on diagnostic accuracy, reporting pooled sensitivity 0.81 and specificity 0.88. It addresses a gap in non-sputum-based LTBI testing, but like the prior biopsychosocial review, it does not establish clinical utility, which the authors note requires further validation.
Doctors are looking for better ways to find people who have hidden tuberculosis. This type of infection stays in the body for a long time and can cause serious illness later. Finding these cases early is very important for public health.
A large review of many studies looked at a specific protein called IP-10. This protein reacts when the body encounters tuberculosis bacteria. The results showed that this test is very good at identifying people who have the infection but are not currently sick.
The test showed high accuracy in both identifying those with the infection and ruling out those without it. Because it works well, it could be a helpful extra tool for doctors to use alongside current skin tests or blood tests.
While the results are very positive, experts say more testing is needed to see how it works in everyday clinics. However, it shows great potential as a reliable way to catch hidden infections early and protect the community.
What this means for you:
The IP-10 protein is a highly accurate marker for identifying hidden tuberculosis infections in high-risk people.
Common questions
What is IP-10 and how does it work?
IP-10 is a protein that the body produces when it reacts to tuberculosis bacteria. This study looked at how well measuring this protein can help doctors identify people with latent tuberculosis infections. It is considered a promising biomarker that could eventually be used alongside current testing methods.
How accurate is the IP-10 test for tuberculosis?
The study found that the IP-10 test had a sensitivity of 0.81 and a specificity of 0.88. These results, along with a high diagnostic odds ratio of 32.56, suggest that the protein is a strong indicator for detecting latent tuberculosis infections in high-risk groups.
Can doctors use this test instead of current methods?
The study suggests that IP-10 could serve as a useful addition to current tests like IGRAs and TST. However, the researchers noted that the clinical use of this test requires further validation before it can be used as a standard tool in medical practice.
BackgroundLatent tuberculosis infection (LTBI) affects nearly a quarter of the world’s population, yet current diagnostic tools are suboptimal. Interferon-γ-inducible protein 10 (IP-10) has been proposed as a candidate biomarker, but its diagnostic value for LTBI among high-risk groups is unclear. To address this, we performed a systematic review and meta-analysis to assess the accuracy of Mycobacterium tuberculosis (Mtb) antigen-induced IP-10 for detecting LTBI among high-risk groups.MethodsPubMed, Web of Science, Embase, Scopus, and the Cochrane Library were searched up to April 2026. Cohort and cross-sectional studies evaluating Mtb antigen-induced IP-10 for LTBI diagnosis in high-risk groups were included. A bivariate random-effects model and a hierarchical summary receiver operating characteristic model were used to estimate and summarize the overall diagnostic performance.ResultsNineteen articles comprising 24 studies (2,014 participants) were included. The pooled sensitivity, specificity, positive and negative likelihood ratios, diagnostic odds ratio, and area under the curve of Mtb antigen-induced IP-10 were 0.81, 0.88, 6.93, 0.21, 32.56, and 0.91, respectively, indicating good diagnostic performance of Mtb antigen-induced IP-10 for detecting LTBI among high-risk groups. The bivariate boxplot, meta-regression and subgroup analysis identified no significant source of heterogeneity.ConclusionMtb antigen-induced IP-10 is a promising biomarker for detecting LTBI among high-risk groups. It may serve as a useful adjunct to IGRAs and TST, although its clinical utility requires further validation.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD420261388089.
